KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Short term Debt (2016 - 2026)

Abbott Laboratories' Short term Debt history spans 18 years, with the latest figure at $4.4 billion for Q1 2026.

  • On a quarterly basis, Short term Debt rose 771.34% to $4.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $4.4 billion, a 771.34% increase, with the full-year FY2025 number at $3.0 billion, up 102.2% from a year prior.
  • Short term Debt hit $4.4 billion in Q1 2026 for Abbott Laboratories, up from $3.0 billion in the prior quarter.
  • Over the last five years, Short term Debt for ABT hit a ceiling of $4.4 billion in Q1 2026 and a floor of $4.0 million in Q1 2022.
  • Historically, Short term Debt has averaged $1.6 billion across 5 years, with a median of $1.5 billion in 2024.
  • Biggest five-year swings in Short term Debt: tumbled 97.99% in 2022 and later soared 57025.0% in 2023.
  • Tracing ABT's Short term Debt over 5 years: stood at $2.3 billion in 2022, then crashed by 52.02% to $1.1 billion in 2023, then skyrocketed by 38.89% to $1.5 billion in 2024, then soared by 102.2% to $3.0 billion in 2025, then surged by 45.37% to $4.4 billion in 2026.
  • Business Quant data shows Short term Debt for ABT at $4.4 billion in Q1 2026, $3.0 billion in Q4 2025, and $1.3 billion in Q3 2025.